Evidence map›Paper›PMID 31843009›Full record

ArticleStem cell research & therapy2019

Genetic tool for fate mapping of Oct4 (Pou5f1)-expressing cells and their progeny past the pluripotency stage.

Andrey A Kuzmin, Veronika V Ermakova, Sergey A Sinenko, Sergey V Ponomartsev, Tatiana Y Starkova, Elena V Skvortsova, Olga Cherepanova, Alexey N Tomilin

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Regulatory Elements Outside EstablishedInternational journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Human AlphoidCells · 2020
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Andrey A KuzminInstitute of Cytology, Russian Academy of Sciences, St. Petersburg, Russian Federation.
Veronika V ErmakovaInstitute of Cytology, Russian Academy of Sciences, St. Petersburg, Russian Federation.
Sergey A SinenkoInstitute of Cytology, Russian Academy of Sciences, St. Petersburg, Russian Federation.
Sergey V PonomartsevInstitute of Cytology, Russian Academy of Sciences, St. Petersburg, Russian Federation.
Tatiana Y StarkovaInstitute of Cytology, Russian Academy of Sciences, St. Petersburg, Russian Federation.
Elena V SkvortsovaInstitute of Cytology, Russian Academy of Sciences, St. Petersburg, Russian Federation.
Olga CherepanovaCleveland Clinic, Lerner Research Institute, Cleveland, OH, USA.
Alexey N TomilinInstitute of Cytology, Russian Academy of Sciences, St. Petersburg, Russian Federation. a.tomilin@incras.ru.ORCID 0000-0002-1137-7167
Institute of Cytology · RUCleveland Clinic Lerner College of Medicine · USSt Petersburg University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethods based on site-specific recombinases are widely used in studying gene activities in vivo and in vitro. In these studies, constitutively active or inducible variants of these recombinases are expressed under the control of either lineage-specific or ubiquitous promoters. However, there is a need for more advanced schemes that combine these features with possibilities to choose a time point from which lineage tracing starts in an autonomous fashion. For example, the key mammalian germline gatekeeper gene Oct4 (Pou5f1) is expressed in the peri-implantation epiblast which gives rise to all cells within embryos. Thus the above techniques are hardly applicable to Oct4 tracing past the epiblast stage, and the establishment of genetic tools addressing such a limitation is a highly relevant pursuit.

methodsThe CRISPR/Cas9 tool was used to manipulate the genome of mouse embryonic stem cells (ESCs), and various cell culture technics-to maintain and differentiate ESCs to neural cell, lentivirus-based reprogramming technique-to generate induced pluripotent stem cells (iPSCs).

resultsIn this paper, we have developed a two-component genetic system (referred to as O4S) that allows tracing Oct4 gene activity past the epiblast stage of development. The first component represents a knock-in of an ubiquitous promoter-driven inducible Cre, serving as a stop signal for downstream tdTomato. Upon activation of Cre activity with 4-hydroxytamoxifen (4-OHT) at any given time point, the recombinase excises a stop signal and poses the second component of the system-the FlpO recombinase, knocked into 3'UTR of Oct4, to be expressed upon activation of the latter gene. Oct4-driven expression of FlpO, in turn, triggers the tdTomato expression and thus, permanently marks Oct4

conclusionsThe developed O4S system can be used to detect Oct4 activation event, both permanent and transient, in somatic cell types outside the germline. The approach can be equally adjusted to other genes, provided the first component of the system is placed under transcriptional control of these genes, thus, making it a valuable tool for cell fate mapping in mice.

Indexed as

AnimalsCell DifferentiationCells, CulturedEmbryonic Stem CellsHumansInduced Pluripotent Stem CellsMiceOctamer Transcription Factor-3TransfectionOctamer Transcription Factor-3POU5F1 protein, humanPou5f1 protein, mouseCre-loxPFlpO-FRTGenome editingMolecular sensorOct4Pou5f1Rosa26

Identifiers

PMID31843009
PMCPMC6916430
OpenAlexW2995428748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.